Brief: Inventiva Announces Late Breaker Abstract From Mid-Stage Trial Evaluating lanifibranor In Combination With empagliflozin
21/10/2024 16:37
Oct 21 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES A LATE BREAKER ABSTRACT FROM LEGEND,
PHASE 2
TRIAL, EVALUATING LANIFIBRANOR IN COMBINATION WITH EMPAGLIFLOZIN
IN MASH AT THE AASLD THE LIVER MEETING® 2024
Source text for Eikon: ID:nGNX3zsyCJ
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030